| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |